2016 updated MASCC/ESMO consensus recommendations: Anticipatory nausea and vomiting in children and adults receiving chemotherapy

Dupuis, L. Lee; Olver, Ian; Aapro, Matti; Molassiotis, Alex

doi:10.1007/s00520-016-3330-z

Cited by 31 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Effectiveness of interventions for nausea has not been well established in young patients (Flank et al, 2016;Stamoulara, Papadopoulou, Perdikaris, & Matziou, 2015). The guideline recommendation is that anticipatory nausea and vomiting may best be prevented through the use of benzodiazepines (Dupuis, Roscoe, Olver, Aapro, & Molassiotis, 2017). For example, parents may be instructed to give a prescribed lorazepam once at bedtime the night before chemotherapy and once the next day before administration of chemotherapy to prevent or treat anticipatory nausea and vomiting in children and adolescents.…”

Section: Cancer Diagnosesmentioning

confidence: 99%

“…For example, parents may be instructed to give a prescribed lorazepam once at bedtime the night before chemotherapy and once the next day before administration of chemotherapy to prevent or treat anticipatory nausea and vomiting in children and adolescents. Another recommendation is the use of behavioral therapies, such as progressive muscle relaxation training, systematic desensitization, and hypnosis (Dupuis et al, 2017). Future studies need to evaluate whether pharmacologic and nonpharmacologic approaches may be effective at home.…”

Section: Cancer Diagnosesmentioning

confidence: 99%

See 1 more Smart Citation

Frequency, Severity, and Distress Associated With Physical and Psychosocial Symptoms at Home in Children and Adolescents With Cancer

Torres¹,

Nunes²,

Silva-Rodrigues³

et al. 2019

Journal of Pediatric Health Care

View full text Add to dashboard Cite

Malignancy-and cancer-related treatments lead to multiple symptoms. Although treatments focus on cure, few research studies have examined the symptoms that accompany these aggressive and complicated treatments. The purpose of the study was to evaluate the symptoms experienced by children at home. Children (n = 25) and adolescents (n = 33) diagnosed with cancer completed the Memorial Symptoms Assessment Scale during the 5 days at home after discharge from the hospital. The most frequent physical

show abstract

Section: Cancer Diagnosesmentioning

confidence: 99%

Section: Cancer Diagnosesmentioning

confidence: 99%

Frequency, Severity, and Distress Associated With Physical and Psychosocial Symptoms at Home in Children and Adolescents With Cancer

Torres¹,

Nunes²,

Silva-Rodrigues³

et al. 2019

Journal of Pediatric Health Care

View full text Add to dashboard Cite

show abstract

“…Our results surprisingly show that children with ALL in maintenance treatment with low-dose MTX (after completed reinductions) had a low level of MTX intolerance and only few patients were affected by anticipatory and associative symptoms, when assessed by their parents. This is remarkable considering that anticipatory and associative nausea and the concept of a conditioned response are well known phenomena associated with the initial high-dose chemotherapy (including high-dose MTX) [22,23]. The majority of patients with ALL must somehow have reversed the conditioned response indicating that there are lessons to be learnt from the ALL group regarding the handling of MTX intolerance.…”

Section: Discussionmentioning

confidence: 99%

Increased methotrexate intolerance in juvenile idiopathic arthritis compared to acute lymphoblastic leukaemia in children

et al. 2019

View full text Add to dashboard Cite

Objectives To analyse the internal consistency of an adaption of the methotrexate intolerance severity score (MISS); and to describe and compare the level of methotrexate intolerance evaluated by the MISS in Danish children with juvenile idiopathic arthritis (JIA) or acute lymphoblastic leukaemia (ALL), treated with low-dose methotrexate (MTX). Methods Cross-sectional study of children diagnosed with JIA or ALL, treated with low-dose MTX, aged 9 years or above, and cognitively intact. The patient’s parents completed the MISS. MTX intolerance was defined as a total MISS score above 6. Results We enrolled 120 children with JIA and 23 children with ALL. The MISS had a good internal consistency in the JIA group. The median MISS score was higher in the JIA group than in the ALL group (JIA: 8; ALL: 1; p<0.0001); and the JIA group had a larger proportion of MTX intolerant children than the ALL group (JIA: 73/120; ALL: 4/23; p<0.001). Within both the JIA group and the ALL group, the MISS total score was not significantly correlated with age, MTX dose or the duration of low-dose MTX treatment. Conclusion In the JIA group the level of MTX intolerance was higher and more attributed to anticipatory, associative and behavioural symptoms than in the ALL group. The MISS may help to uncover whether MTX intolerance is present and which aspects are affected in the individual patient, thus guiding intervention. The MISS may also be applicable within leukaemia care.

show abstract

“…In Case 1, no granulocyte colony-stimulating factor preparations were administered. As for antiemetic drugs, palonosetron and dexamethasone were administered in Case 1 as described by Takatori et al ( 12 ), while a three-drug combination of aprepitant, palonosetron, and dexamethasone was administered in Case 2 according to the Multinational Association of Supportive Care in Cancer/European Society for Medical Oncology Antiemetic Guidelines ( 13 ). As a result, neither grade 2 or higher nausea nor vomiting was observed.…”

Section: Discussionmentioning

confidence: 99%

Safe administration of bevacizumab combination chemotherapy for the patients with recurrent cervical cancer after pelvic radiotherapy: Two case reports

et al. 2018

View full text Add to dashboard Cite

In Japan, bevacizumab has not been proven either effective or safe for the treatment of recurrent cervical cancer. The present study reported two cases in which bevacizumab combination chemotherapy was safely administered for recurrent cervical cancer following pelvic radiotherapy. Case 1 was a 62-year-old woman with stage IIIB squamous cell carcinoma of the cervix who had received whole pelvic external beam radiotherapy (WPEBRT) at a dose of 50.4 Gy and high dose rate intra-cavitary brachytherapy at a dose of 24 Gy to the pelvis one year earlier. For recurrent cervical cancer, chemotherapy with paclitaxel, carboplatin and bevacizumab was administered for six cycles. Case 2 was a 52-year-old woman with stage IIB squamous cell carcinoma of the cervix who had received WPEBRT at a dose of 50.4 Gy to the pelvis 11 years earlier. For lymph node and liver metastases, chemotherapy with paclitaxel, cisplatin, and bevacizumab was administered for six cycles. Although grade 2 proteinuria was observed in one of these patients, there were no intestinal perforation, fistula, hypertension, proteinuria or thrombosis events, which are the characteristic adverse reactions associated with bevacizumab. Hematotoxicity was also manageable. Regarding the antitumor effect, case 1 demonstrated a complete response, whereas case 2 resulted in stable disease.

show abstract

2016 updated MASCC/ESMO consensus recommendations: Anticipatory nausea and vomiting in children and adults receiving chemotherapy

Cited by 31 publications

References 26 publications

Frequency, Severity, and Distress Associated With Physical and Psychosocial Symptoms at Home in Children and Adolescents With Cancer

Frequency, Severity, and Distress Associated With Physical and Psychosocial Symptoms at Home in Children and Adolescents With Cancer

Increased methotrexate intolerance in juvenile idiopathic arthritis compared to acute lymphoblastic leukaemia in children

Safe administration of bevacizumab combination chemotherapy for the patients with recurrent cervical cancer after pelvic radiotherapy: Two case reports

Contact Info

Product

Resources

About